Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

NCT02613598 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin

Interventions

DRUG: Bortezomib
DRUG: Ruxolitinib

Sponsor

University of Michigan Rogel Cancer Center